About bioxcel therapeutics inc - BTAI
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
BTAI At a Glance
BioXcel Therapeutics, Inc.
555 Long Wharf Drive
New Haven, Connecticut 06511
| Phone | 1-475-238-6837 | Revenue | 2.27M | |
| Industry | Biotechnology | Net Income | -59,599,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 64.203% | |
| Fiscal Year-end | 12 / 2025 | Employees | 37 | |
| View SEC Filings |
BTAI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 6.693 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.397 |
| Enterprise Value to Sales | 38.949 |
| Total Debt to Enterprise Value | 1.166 |
BTAI Efficiency
| Revenue/Employee | 61,243.243 |
| Income Per Employee | -1,610,783.784 |
| Receivables Turnover | 17.298 |
| Total Asset Turnover | 0.04 |
BTAI Liquidity
| Current Ratio | 1.682 |
| Quick Ratio | 1.651 |
| Cash Ratio | 1.343 |
BTAI Profitability
| Gross Margin | -8.208 |
| Operating Margin | -2,801.147 |
| Pretax Margin | -2,630.141 |
| Net Margin | -2,630.141 |
| Return on Assets | -106.389 |
| Return on Equity | N/A |
| Return on Total Capital | -605.312 |
| Return on Invested Capital | -220.729 |
BTAI Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 1,045.572 |
| Total Debt to Total Assets | 268.525 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 1,041.773 |